Surface Oncology (SURF) Stock Price, News & Analysis

Company Overview

Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 which is in phase II clinical trial targeting interleukin 27; GSK4381562, an antibody targeting CD112R, an inhibitory protein expressed on natural killer and T cells; and SRF114 that is in phase 1/2 clinical trials targeting the chemokine receptor CCR8. Surface Oncology, Inc. has a license agreement with GlaxoSmithKline Intellectual Property (No. 4) Limited and Vaccinex, Inc. to develop, manufacture, and commercialize antibodies, which targets SRF114. The company was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. As of September 8, 2023, Surface Oncology, Inc. operates as a subsidiary of Coherus BioSciences, Inc.

Key Stats

• Today's Range: $1.07 to $1.07
• 50-Day Range: $0.88 to $1.08
• 52-Week Range: $0.56 to $1.43
• Volume: N/A
• Average Volume: 430,375 shs
• Market Capitalization: $65.08 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

SURF Stock Analysis - Frequently Asked Questions

How were Surface Oncology's earnings last quarter?

Surface Oncology, Inc. (NASDAQ:SURF) announced its earnings results on Thursday, November, 4th. The company reported ($0.44) earnings per share for the quarter, missing the consensus estimate of ($0.40) by $0.04. The firm had revenue of $0.39 million for the quarter.

When did Surface Oncology IPO?

Surface Oncology (SURF) raised $84 million in an initial public offering (IPO) on Thursday, April 19th 2018. The company issued 6,000,000 shares at $13.00-$15.00 per share. Goldman Sachs, Cowen and Evercore ISI served as the underwriters for the IPO.

What other stocks do shareholders of Surface Oncology own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Surface Oncology investors own include Meta Platforms (META), NVIDIA (NVDA), CrowdStrike (CRWD), NIO (NIO), Zoom Video Communications (ZM), QUALCOMM (QCOM) and Workhorse Group (WKHS).

Company Calendar

• Last Earnings: 11/04/2021
• Today: 5/30/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: NASDAQ:SURF
• CIK: 1718108
• Web: www.surfaceoncology.com
• Phone: (617) 714-4096
• Fax: N/A
• Employees: 35
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($1.53)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$63.59 million
• Net Margins: N/A
• Pretax Margin: -211.95%
• Return on Equity: -107.81%
• Return on Assets: -65.57%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.60
• Quick Ratio: 3.60

Sales & Book Value

• Annual Sales: $30 million
• Price / Sales: 2.17
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.81 per share
• Price / Book: 1.32

Miscellaneous

• Outstanding Shares: 60,824,000
• Free Float: 53,525,000
• Market Cap: $65.08 million
• Optionable: Not Optionable
• Beta: 1.75